<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Aurora family of kinases, play a fundamental role in cell division and are overexpressed in several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> including colon </plain></SENT>
<SENT sid="1" pm="."><plain>The activity of barasertib-hQPA, a sele-ctive inhibitor of Aurora-B kinase (ABK) was investigated in a range of preclinical models of <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment with barasertib-hQPA produced anti-proliferative and cytotoxic effects across a panel of human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cell lines in vitro </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="50266">Prodrug</z:chebi>, barasertib [48-h subcutaneous (s.c.) infusion; 150 mg/kg/day] inhibited the growth of SW620, Colo205, HCT116 human <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> xenografts in <z:mp ids='MP_0003815'>nude</z:mp> mice significantly (Student's t-test, P&lt;0.05, n=10-12 per group) </plain></SENT>
<SENT sid="4" pm="."><plain>Flow cytometric analysis of single cells from disaggregated barasertib-treated SW620 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> revealed a decrease in phosphorylated <z:chebi fb="0" ids="15358">histone</z:chebi> H3 (phH3) and an increase in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells with ≥4N DNA content P&lt;0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>The activity of barasertib was then examined in ApcMin/+ mice, a spontaneous model of early intestinal <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Macroscopic evaluation of the small intestine revealed that barasertib treatment [25 mg/kg intra-peritoneal (i.p.) Q1Dx4 each week for 3 weeks] of 8-week old ApcMin/+ mice produced a 39% reduction in macroadenoma number (P=0.02) and a 43% reduction in overall <z:mpath ids='MPATH_270'>adenoma</z:mpath> burden (P=0.02) compared with vehicle-treated controls </plain></SENT>
<SENT sid="7" pm="."><plain>Quantification of microscopic <z:mpath ids='MPATH_270'>adenomas</z:mpath> revealed a &gt;64% reduction in the number of <z:mpath ids='MPATH_270'>adenomas</z:mpath> spanning more than one villus </plain></SENT>
<SENT sid="8" pm="."><plain>Histological analysis of these <z:mpath ids='MPATH_270'>adenomas</z:mpath> revealed a number of distinct changes in barasertib-treated ApcMin/+ mice, including a 94% reduction in the proportion of phospho-<z:chebi fb="0" ids="15358">histone</z:chebi> H3-positive cells (P&lt;0.001) and a 53% reduction in the number of cells per <z:mpath ids='MPATH_270'>adenoma</z:mpath> (P=0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>These results provide a scientific rationale for investigating ABK inhibitors as a treatment for <z:e sem="disease" ids="C0346627" disease_type="Neoplastic Process" abbrv="">intestinal cancer</z:e> </plain></SENT>
</text></document>